INmune Bio, Inc. (INMB)
Oxford Ledge is still expanding full research coverage of INMB. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
INmune Bio develops immune-reprogramming therapies, focusing on CORDStrom for rare skin disease treatment.
SEC filings
- 8-K Entry into material agreement; Financial statements and exhibits 2026-07-01
- 8-K Other material event; Financial statements and exhibits 2026-06-23
- 8-K Departure/election of directors or officers; Shareholder vote results; Financial statements and exhibits 2026-06-17
- 8-K Other material event; Financial statements and exhibits 2026-06-02
- 8-K Other material event; Financial statements and exhibits 2026-05-14
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for INMB. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open INMB in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.